KRAS G12S

P1/2, N=67, Recruiting, D3 Bio (Wuxi) Co., Ltd | Active, not recruiting --> Recruiting | Trial completion date: Apr 2028 --> Aug 2028 | Trial primary completion date: Apr 2028 --> Aug 2028

P1, N=76, Not yet recruiting, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.

P1/2, N=265, Recruiting, Blueprint Medicines Corporation

P1, N=665, Recruiting, TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | N=387 --> 665

CAC exhibits distinct mutational characteristics compared with sporadic CRC and different genetic abnormalities in each lesion may contribute to the dysplasia-carcinoma sequence.

When combined with cytotoxic agents, including paclitaxel, SN38, gemcitabine and cisplatin, MRTX1133 reduced the sensitivity to cell cycle-dependent chemotherapeutic agents, namely paclitaxel, SN38 and gemcitabine, while not affecting the activity of the non-cell cycle-dependent agent cisplatin. The present study therefore provided preclinical evidence for the potential utility of KRAS (G12D)-targeted therapy in OMC and highlights the importance of sequential rather than concurrent scheduling of MRTX1133 with cell cycle-dependent chemotherapy to optimize therapeutic efficacy.

P1, N=48, Not yet recruiting, Kumquat Biosciences Inc.

The uncommon KRAS mutation group had numerically inferior progression-free survival (PFS) and overall survival (OS); however, this difference did not reach statistical significance in our study (mean PFS: 15.14 months vs. 30.39 months, p = 0.074; mean OS: 24.50 months vs. 38.79 months, p = 0.157). These findings underscore the value of broad molecular profiling in establishing critical links between specific morphologic features, genetic alterations, and clinical behavior for tumors harboring these uncommon KRAS variants.

P1, N=750, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting

BRAF V600E was detected in 3.7%.ConclusionsWe report a rise in EOCRC in Serbia, especially in ages 45-49, and recommend policy makers to lower the screening age to 45. We present the first detailed molecular profile of Serbian EOCRC and recommend that policy makers implement routine KRAS variant testing and ensure access to KRAS G12C-targeted therapies to improve personalized care.

IsoPS-DIA is compatible with both Orbitrap and quadrupole time-of-flight mass spectrometry (Q-TOF) platforms using standard software, and we provide an open-source window-design tool to facilitate adoption. These results demonstrate the unique capability of IsoPS-DIA to bridge genotype and proteotype through precise, scalable, and reproducible quantification, offering a broadly applicable platform for precision oncology and other applications.

Six months after the surgery, metastasis was found in the liver, but at the request of the patient and their family, the decision was made not to undergo any aggressive treatment. We describe the clinical and pathological features of colorectal YST-like carcinoma that aid in its accurate diagnosis and provide treatment suggestions.